A Study of Lung Cancer Screening in People With Unexplained Weight Loss
Memorial Sloan Kettering Cancer Center · with AstraZeneca · NCT06717334
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 50–80 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 409
- US sites recruiting
- 8
- Study start
- December 2, 2024
- Record last updated
- October 9, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The researchers are doing this study to see if people with unexplained weight loss who have lung cancer screening are more likely to have or develop lung cancer than people without unexplained weight loss. The lung cancer screening will involve use of low-dose computed tomography (LDCT), a CT scan that gives off very low doses of radiation and can make detailed pictures of the lungs to help find tumors. The study researchers will also analyze participants' blood samples to determine if blood testing can be used to help to diagnose lung cancer.
Being studied: Low Dose CT imaging; blood draws; screening questionnaire
Conditions: Lung Cancer Screening
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Eligible for American Cancer Society lung cancer screening, as follows as per the discretion of the screening team:
- Age 50-80 years old
- At least 20-pack year history of smoking
- Weight loss of 3-10%, defined as UWL, within any timeframe over the past in the 18 months prior to enrollment, that cannot be attributed to an underlying medical condition at the discretion of the enrolling investigator
- Note that patients who have 3-10% weight may still be enrolled if the enrolling investigator does not conclude that the weight loss can be attributed to the patient's intentional efforts.
- Documented weight loss can be self-reported or extracted from weights obtained during physician visits. However, if self-reported weight loss is contradicted by weight loss documented in the medical record (e.g. a patients states that (s)he lost 10 lbs in the past 6 months, but a weight documented in the medical record does not support that history), the measured and quantified weight change will be used to ascertain eligibility
- Life expectancy greater than 1 year, per assessment of the treating clinician.
Exclusion Criteria
- Currently pregnant or trying to become pregnant via self-report
- Prior history of recent CT scan of the chest either through LDCT screening or with a scan of the chest (standard, not LDCT) performed within the past 12 months
- Prior history of NSCLC
○ Note that patients with a history of diagnosis of non-lung cancers are eligible for the study.
- Currently undergoing or referred for diagnostic evaluation due to clinical suspicion for malignancy (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality).
- Patients with a germline pathogenic genetic variant who have undergone whole body MRI within the past 12 months
- Unable to comply with study procedures
Recruiting US locations
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
Basking Ridge, NJ 07920
Site contact: Alexis Chidi, MD, PhD · 212-639-8100
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, NJ 07748
Site contact: Alexis Chidi, MD, PhD · 212-639-8100
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, NJ 07645
Site contact: Alexis Chidi, MD, PhD · 212-639-8100
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)
Commack, NY 11725
Site contact: Alexis Chidi, MD, PhD · 212-639-8100
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, NY 10604
Site contact: Alexis Chidi, MD, PhD · 212-639-8100
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, NY 10065
Site contact: Alexis Chidi, MD, PhD · 212-639-8100
Montefiore Health Systems (Montefiore Medical Center)
The Bronx, NY 10467
Site contact: Neel Chudgar, MD · 718-920-8874
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, NY 11553
Site contact: Alexis Chidi, MD, PhD · 212-639-8100
Study contacts (from the official record)
- Alexis Chidi, MD, PhD · 212-639-8100 · chidia1@mskcc.org
- Bernard Park, MD · 646-888-3346
Similar studies in New Jersey
All weight loss studies in New Jersey →- RecruitingPhase 2
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Eli Lilly and Company
- Location
- Pennington, NJ + 24 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
- Location
- Somerset, NJ + 136 other US sites
- Eligibility basics
- Ages 45–99
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
- Location
- Eatontown, NJ + 59 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Warren Township, NJ + 68 other US sites
- Eligibility basics
- Ages 18+